April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
African Descent And Glaucoma Evaluation Study (ADAGES): The Relationship Between Central Corneal Thickness And Measures Of Disease Severity In African Descendents And European Descendents With Glaucoma
Pooya Banapour; Jeffrey M. Liebmann; Christopher A. Girkin; Mauro T. Leite; Linda M. Zangwill; Robert N. Weinreb; Pamela A. Sample; Felipe M. Medeiros
Author Affiliations & Notes
  • Pooya Banapour
    Hamilton Glaucoma Center, Univ of California-San Diego, La Jolla, California
  • Jeffrey M. Liebmann
    Ophthalmology, NYU School of Medicine, New York, New York
  • Christopher A. Girkin
    Ophthalmology, Univ of Alabama at Birmingham, Birmingham, Alabama
  • Mauro T. Leite
    Hamilton Glaucoma Center, Univ of California-San Diego, La Jolla, California
  • Linda M. Zangwill
    Hamilton Glaucoma Center, Univ of California-San Diego, La Jolla, California
  • Robert N. Weinreb
    Hamilton Glaucoma Center, Univ of California-San Diego, La Jolla, California
  • Pamela A. Sample
    Hamilton Glaucoma Center, Univ of California-San Diego, La Jolla, California
  • Felipe M. Medeiros
    Hamilton Glaucoma Center, Univ of California-San Diego, La Jolla, California
  • Footnotes
    Commercial Relationships  Pooya Banapour, None; Jeffrey M. Liebmann, Alcon Laboratories Inc. (C), Allergan Inc. (C), Carl Zeiss Meditec (F), Dyopsis Corp. (F, C), Heidelberg Engineering (F), Optovue Inc. (F, C), Pfizer Inc. (C), Topcon Medical Systems Inc. (F, C); Christopher A. Girkin, Alcon Laboratories Inc. (C), Allergan Inc. (C), Heidelberg Engineering Inc. (R), Merck Inc. (R), Optive Inc. (R), Pfizer Inc. (C); Mauro T. Leite, None; Linda M. Zangwill, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering (R), Heidelberg Engineering GmbH (F), Optovue Inc. (F), Topcon Medical Systems Inc. (F); Robert N. Weinreb, Alcon (C), Allergan Inc. (C), Carl Zeiss Meditec (F, C), Heidelberg Engineering GmbH (F), Merck (C), Novartis (F), Optovue (F, C), Pfizer (C), Topcon Medical Systems (F); Pamela A. Sample, None; Felipe M. Medeiros, Alcon Laboratories Inc. (F, R), Alcon Labortories Inc. (C), Allergan Inc. (C, R), Carl Zeiss (R), Carl Zeiss Meditec Inc. (F), Merck Inc. (F), Pfizer Inc. (F, C)
  • Footnotes
    Support  NIH Grant T32
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5025. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      African Descent And Glaucoma Evaluation Study (ADAGES): The Relationship Between Central Corneal Thickness And Measures Of Disease Severity In African Descendents And European Descendents With Glaucoma
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Pooya Banapour, Jeffrey M. Liebmann, Christopher A. Girkin, Mauro T. Leite, Linda M. Zangwill, Robert N. Weinreb, Pamela A. Sample, Felipe M. Medeiros; African Descent And Glaucoma Evaluation Study (ADAGES): The Relationship Between Central Corneal Thickness And Measures Of Disease Severity In African Descendents And European Descendents With Glaucoma. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5025.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To evaluate the relationship between central corneal thickness (CCT) and glaucoma severity in subjects of African descent (AD) and European descent (ED).

Methods: : 1194 eyes (639 in ED, 555 in AD) of 834 glaucoma patients and glaucoma suspects recruited from the Diagnostic Innovations in Glaucoma Study (DIGS) and from the African Descent and Glaucoma Evaluation Study (ADAGES) were included in this cross-sectional study. Participants underwent imaging with the GDx with enhanced corneal compensation (ECC) and the Heidelberg retina tomograph (HRT). Disease severity was measured by visual field mean deviation (MD), global retinal nerve fiber layer (RNFL) thickness and rim area (RA). Univariable and multivariable regression models were built to evaluate the associations between disease severity and CCT in AD and ED.

Results: : AD participants had significantly thinner CCT (533µm vs 555µm), lower MD (-3.37dB vs. -2.51dB), thinner RNFL (47.06µm vs 48.18µm) and larger RA (1.34mm2 vs 1.21mm2) and disc area (DA) (2.20mm2 vs 1.88mm2) compared to ED participants (all P<0.007). A significant relationship was found between CCT and measures of disease severity in both racial groups (all P<0.04). Each 40µm decrease in CCT resulted in a decrease in MD of 1.22dB in ED and 0.62dB in AD (P=0.068), a decrease in RA of 0.07mm2 in ED and 0.03mm2 in AD (P=0.234) and a decrease in RNFL thickness of 2.4µm in ED and 1.1µm in AD (P=0.045). After adjusting for CCT, age, DA and IOPmax, no significant difference was found between races for measures of disease severity.

Conclusions: : CCT was significantly associated with measures of disease severity in AD and ED participants. After adjustment for CCT, age, DA and IOPmax, no significant differences in measures of disease severity between the two racial groups were observed.

Keywords: clinical (human) or epidemiologic studies: prevalence/incidence • clinical (human) or epidemiologic studies: prevalence/incidence • cornea: clinical science 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept